Provided by Tiger Fintech (Singapore) Pte. Ltd.

Janux Therapeutics, Inc.

25.56
-0.8100-3.07%
Post-market: 25.560.00000.00%18:23 EDT
Volume:742.30K
Turnover:19.32M
Market Cap:1.51B
PE:-19.91
High:28.13
Open:26.25
Low:25.44
Close:26.37
Loading ...

Janux Therapeutics Launches $300 Million Offering

MT Newswires Live
·
04 Dec 2024

Janux Therapeutics Announces Proposed Public Offering

THOMSON REUTERS
·
04 Dec 2024

Janux Therapeutics Announces Proposed Public Offering

Business Wire
·
04 Dec 2024

Sector Update: Health Care Stocks Higher Tuesday Afternoon

MT Newswires Live
·
04 Dec 2024

Janux Therapeutics Shares Soar After Reporting 'Positive' Interim Data for JANX007 in Prostate Cancer Patients

MT Newswires Live
·
04 Dec 2024

Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz

GuruFocus.com
·
04 Dec 2024

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results -- Barrons.com

Dow Jones
·
03 Dec 2024

Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year

GuruFocus.com
·
03 Dec 2024

Stifel Nicolaus Adjusts Janux Therapeutics Price Target to $115 From $70, Maintains Buy Rating

MT Newswires Live
·
03 Dec 2024

Janux Therapeutics price target raised to $115 from $70 at Stifel

TIPRANKS
·
03 Dec 2024

Scotiabank Raises Price Target on Janux Therapeutics to $62 From $42, Keeps Sector Perform Rating

MT Newswires Live
·
03 Dec 2024

Top Premarket Gainers

MT Newswires Live
·
03 Dec 2024

Janux Therapeutics price target raised to $91 from $79 at Leerink

TIPRANKS
·
03 Dec 2024

Janux Therapeutics Inc : Scotiabank Raises Target Price to $62 From $42

THOMSON REUTERS
·
03 Dec 2024

Janux Therapeutics price target raised to $200 from $100 at Cantor Fitzgerald

TIPRANKS
·
03 Dec 2024

BUZZ-Janux soars as early data of cancer drug exceeds expectations

Reuters
·
03 Dec 2024

Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
03 Dec 2024

Buy Rating Affirmed for Janux Therapeutics Inc. Amid Promising Clinical Data and Strategic Advancements

TIPRANKS
·
03 Dec 2024

Janux Therapeutics Shares Soar 66% Premarket After Co Reports Strong Early-Stage Data for Prostate Cancer Drug

THOMSON REUTERS
·
03 Dec 2024

Janux Therapeutics price target raised to $70 from $63 at H.C. Wainwright

TIPRANKS
·
03 Dec 2024